Cytokinetics, Incorporated
CYTK
$74.13
$0.680.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 28.62M | 19.36M | 17.76M | 1.94M | 66.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.62M | 19.36M | 17.76M | 1.94M | 66.77M |
| Cost of Revenue | 103.40M | 98.08M | 104.40M | 99.23M | 112.55M |
| Gross Profit | -74.78M | -78.72M | -86.64M | -97.30M | -45.79M |
| SG&A Expenses | 104.40M | 104.90M | 91.72M | 69.46M | 65.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 207.80M | 202.97M | 196.12M | 168.69M | 178.28M |
| Operating Income | -179.17M | -183.62M | -178.37M | -166.76M | -111.51M |
| Income Before Tax | -198.76M | -206.03M | -183.03M | -306.18M | -134.37M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -198.76M | -206.03M | -183.03M | -306.18M | -134.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -198.76M | -206.03M | -183.03M | -306.18M | -134.37M |
| EBIT | -179.17M | -183.62M | -178.37M | -166.76M | -111.51M |
| EBITDA | -175.54M | -180.24M | -175.51M | -164.08M | -109.22M |
| EPS Basic | -1.50 | -1.67 | -1.52 | -2.55 | -1.12 |
| Normalized Basic EPS | -0.94 | -1.04 | -0.95 | -0.96 | -0.70 |
| EPS Diluted | -1.50 | -1.67 | -1.52 | -2.55 | -1.12 |
| Normalized Diluted EPS | -0.94 | -1.04 | -0.95 | -0.96 | -0.70 |
| Average Basic Shares Outstanding | 132.09M | 123.27M | 120.10M | 119.98M | 119.46M |
| Average Diluted Shares Outstanding | 132.09M | 123.27M | 120.10M | 119.98M | 119.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |